{"preliminary_commentary":{"by_channel":{"x_thread":12,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03341845\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["axitinib","avelumab"]],"indication":"localized clear-cell renal cell carcinoma","name":"NEOAVAX","nct_id":"NCT03341845","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neoavax-nct03341845. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"axitinib 5MG BID and avelumab 10mg/kg Q2W","label":"axitinib and avelumab","type":"EXPERIMENTAL"}],"collaborators":["Pfizer"],"completion_date":{"date":"2025-01-31","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":40,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Axitinib","otherNames":[],"type":"DRUG"},{"name":"Avelumab","otherNames":[],"type":"DRUG"}],"last_update":"2018-05-21","lead_sponsor":"The Netherlands Cancer Institute","official_title":"Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC and a Moderate to High Risk","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2023-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"number of patients with partial remission","timeFrame":"week 12 of neoadjuvant treatment"}],"references":[{"citation":"Bex A, van Thienen JV, Schrier M, Graafland N, Kuusk T, Hendricksen K, Lagerveld B, Zondervan P, van Moorselaar JA, Blank C, Wilgenhof S, Haanen J. A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). Future Oncol. 2019 Jul;15(19):2203-2209. doi: 10.2217/fon-2019-0111. Epub 2019 Apr 26.","pmid":"31023100","type":"DERIVED"}],"start_date":{"date":"2018-03-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC","url":"https://clinicaltrials.gov/study/NCT03341845"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neoavax-nct03341845"}